Compare · BOLT vs JNJ
BOLT vs JNJ
Side-by-side comparison of Bolt Biotherapeutics Inc. (BOLT) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BOLT and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 74730.8x BOLT ($8.2M).
- Over the past year, BOLT is down 28.1% and JNJ is up 31.9% - JNJ leads by 60.0 points.
- JNJ has been more active in the news (11 items in the past 4 weeks vs 1 for BOLT).
- JNJ has more recent analyst coverage (25 ratings vs 6 for BOLT).
- Company
- Bolt Biotherapeutics Inc.
- Johnson & Johnson
- Price
- $4.29-5.20%
- $255.53+0.88%
- Market cap
- $8.2M
- $610.38B
- 1M return
- +27.53%
- -5.45%
- 1Y return
- -28.10%
- +31.89%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 11
- Recent ratings
- 6
- 25
Bolt Biotherapeutics Inc.
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest BOLT
- SEC Form 8-K filed by Bolt Biotherapeutics Inc.
- President, CEO and CFO Quinn William P. bought $2,469 worth of shares (637 units at $3.88) and sold $58,402 worth of shares (17,566 units at $3.32), increasing direct ownership by 997% to 25,384 units (SEC Form 4) to satisfy withholding tax
- Senior VP, Finance and PAO Nemec Sarah bought $1,973 worth of shares (509 units at $3.88) and sold $26,072 worth of shares (7,842 units at $3.32), increasing direct ownership by 1,107% to 17,082 units (SEC Form 4) to satisfy withholding tax
- Chief Operating Officer Yonehiro Grant sold $43,807 worth of shares (13,176 units at $3.32), decreasing direct ownership by 43% to 17,269 units (SEC Form 4) to satisfy tax liability
- SEC Form SCHEDULE 13G filed by Bolt Biotherapeutics Inc.
- SEC Form 10-Q filed by Bolt Biotherapeutics Inc.
- Bolt Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Rodman & Renshaw initiated coverage on Bolt Biotherapeutics with a new price target
- SEC Form 10-Q filed by Bolt Biotherapeutics Inc.
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause